SAN DIEGO, Nov. 1 /PRNewswire/ -- ASTRO, the annual meeting of the American Society for Therapeutic Radiology and Oncology, marks the introduction of Vero SBRT to the broader North American audience.
The Vero SBRT system offers the latest in radiation technology: dynamic tumor tracking and advanced real-time imaging delivered with high mechanical accuracy. Vero’s integration and precision dose delivery unleash a new era in speed, accuracy and versatility. A feat of engineering, Vero represents over 20 years of research to combine Intensity Modulated Radiotherapy (IMRT), Image Guided Radiotherapy (IGRT) and real-time tumor tracking into one treatment delivery system. Vero offers advanced imaging, treatment planning and delivery.
“With its unique, dynamic tracking capabilities, coupled with advanced real-time imaging and ability to treat from nearly any direction, Vero is the ultimate SBRT platform,” explains Timothy Solberg, PhD.
Stereotactic Body Radiotherapy (SBRT) involves efficient delivery of precisely focused, high-energy radiation to a localized area to destroy tumors throughout the body that often cannot be addressed by conventional surgery, including malignant and benign lesions, especially for lung, liver, prostate, spine, head and neck, and many other extra-cranial indications.
“We have started clinically evaluating, designing clinical treatment protocols and conducting applied researchat the University of Brussels, Belgium and the first patient was treated recently,” explains Herbert Frosch, managing director for Vero GmbH. “This promising new system may offer better treatment results with fewer side effects compared to other cancer treatment methods, especially when it comes to the treatment of moving targets like lung or liver tumors. The promises of fewer side effects and more efficient treatments mean that patients can now benefit from this groundbreaking innovation refined for high-precision cancer treatment. Vero is designed to drive shorter treatment times, higher patient throughput and increased patient access.”
About Vero SBRT
Vero SBRT is a cooperative partnership between Brainlab AG and Mitsubishi Heavy Industries Ltd. Brainlab develops the motion management and software technology and is an award-winning innovator in image-guided surgery, radiotherapy and radiosurgery. Mitsubishi Heavy Industries Ltd. develops the MHI-TM2000 linear accelerator system capable of precise identification of tumor location and exact targeting of x-ray irradiation.
SOURCE Vero SBRT
